Komori
Presentation on financial results4875MediciNova,Inc.Pharmaceuticals

Supplementary Explanatory Materials for the Third Quarter Financial Results for the Fiscal Year Ending December 2026

For the nine months ended September 2026, operating revenue was ¥123.507 million, and both operating and net losses narrowed year on year. Meanwhile, clinical trials such as those for ALS showed progress, including completion of patient enrollment and completion of the last patient’s final visit.

Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
123507
¥ thousand
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation on financial resultsFiscal year ending December 2026, third quarter1 item taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales783,978 US dollars ¥123.507 million
Operating profit-8,437,219 US dollars −¥1,329.199 million
Net income-7,743,359 US dollars −¥1,219.888 million
Selling, general and administrative expenses5,287,236 US dollars ¥832.951 million
Results for the three months of the current quarter
Operating revenue
138,555 US dollars ¥21.827 million
Research and development expenses and patent expenses
1,248,796 US dollars ¥196.735 million
General and administrative expenses
1,867,277 US dollars ¥294.17 million
Service Cost of Revenue
82,706 US dollars ¥13.029 million
Operating profit
-3,060,224 US dollars −¥482.107 million
Net income for the current fiscal year
-2,842,962 US dollars −¥447.88 million
What the company explained in this material
Key KPIsA metric the company considers important as a management benchmark.
  • SEANOBI-ALS target patient enrollment200 People
  • Number of patients enrolled in COMBAT-ALS234 People
  • Number of target patients in MN-001-NATG-20240 People
  • SEANOBI-ALS treatment duration6 months
  • MN-001-NATG-202 treatment duration24 Weekly
Contents of this document
ItemDetails
Document typePresentation on financial results
Fiscal Period CoveredFiscal year ending December 2026, third quarter
Net Sales783,978 US dollars (¥123.507 million)
Operating profit-8,437,219 US dollars (−¥1,329.199 million)
Net income-7,743,359 US dollars (−¥1,219.888 million)
Selling, general and administrative expenses5,287,236 US dollars (¥832.951 million)
Results for the three months of the current quarterOperating revenue 138,555 US dollars (¥21.827 million) / Research and development expenses and patent expenses 1,248,796 US dollars (¥196.735 million) / General and administrative expenses 1,867,277 US dollars (¥294.17 million) / Service Cost of Revenue 82,706 US dollars (¥13.029 million) / Operating profit -3,060,224 US dollars (−¥482.107 million) / Net income for the current fiscal year -2,842,962 US dollars (−¥447.88 million)
Key KPIsIndicator name SEANOBI-ALS target patient enrollment / Value 200 People / Year on year against the same period last year Not disclosed, Indicator name Number of patients enrolled in COMBAT-ALS / Value 234 People / Year on year against the same period last year Not disclosed, Indicator name Number of target patients in MN-001-NATG-202 / Value 40 People / Year on year against the same period last year Not disclosed, Indicator name SEANOBI-ALS treatment duration / Value 6 months / Year on year against the same period last year Not disclosed, Indicator name MN-001-NATG-202 treatment duration / Value 24 Weekly / Year on year against the same period last year Not disclosed
Items this document does not state (23)
Ordinary incomeGross Profit MarginOperating profit marginFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No specific reasons for the changes in results have been disclosed. In research and development, progress has been described as completion of enrollment of the target 200 patients in SEANOBI-ALS, completion of the last patient’s final visit during the double-blind treatment period in COMBAT-ALS, and the release of top-line data for MN-001-NATG-202.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.